


### Goal and Objectives of this ECHO


- To create a virtual learning environment that fosters knowledge exchange and guidance for jail teams as they strengthen their capacity to implement and/or enhance access to Medication for Opioid Use Disorder (MOUD) in their setting.
- Objective 1: To increase knowledge of best practices in MOUD implementation in county jails.
- Objective 2: To build capacity among multidisciplinary jail teams for deploying strategies for successful MOUD implementation in county jails.


## Your Goals for Participation What are you/your team hoping to leave this experience with?


















Anatomy of a TeleECHO Clinic


1. Introductions & announcements
2. Case Presentation
3. Brief Didactic (10-30 minutes)
4. Closing announcements
5. Post-clinic evaluation (required for educational credit)


































DISCLOSURES	
Faculty	Nature of Commercial Interest
Jean Glossa, MD, MBA, FACP	Dr. Glossa discloses she is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of healthcare clients.
Shannon Robinson, MD	Dr. Robinson discloses she is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of healthcare clients.
R. Corey Waller, MD, MS, FACEP, DFASAM	Dr. Waller discloses he is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of healthcare clients.
Jeanene Smith, MD, MPH (Curriculum Advisor)	Dr. Smith discloses she is an employee of Health Management Associates, a national research and consulting firm providing technical assistance to a diverse group of healthcare clients.
HEALTH MANAGEMENT ASSOCIATE.	Copyright © 2023 restills Management Association, No. 455 orgins reserved. PROFESTOR and CENSIONERS. 49






























Once someone meets criteria for a substance use disorder, their ability to make a "decision" is not so simple.
 Medication for Opioid Use Disorder (OUD) is standard of care, period.
 It takes time and persistence to change the neurobiology of something that developed over many years.
 Sometimes we cannot change it at all.





# | Withdrawing opioid agonists leaves a patient in dopamine depleted state: | Patients will focus on obtaining substances to increase dopamine and are | Unable to focus on rehabilitation efforts | Morbidity & mortality while incarcerated decreased: | Death associated with withdrawal, ODs, HCV, suicidality, violence, workman's compensation claims... | Decreased mortality upon release & reincarceration | Increased employment post release | Continuation of MAT (vs. forced withdrawal) leads to better outcomes | Starting MAT during incarceration leads to better outcomes than referral to treatment | Increased treatment retention and decreased opioid use (Kinlock, 2009) | 61% reduction in mortality post release (Greene, 2018)



### 

# Figure 1. C et al. Post incarceration fatal overdose after implementing medication assisted treatment in a statewide correctional system. JAMA Psychiatry 2018; 5(4):405-407. doi:10.1001/jamapsychiatry.2017.4614 Kilnoick, TW et al. A randomised controlled trial of methadone maintenance for prisoners: results at twelve-months post release. J Substance Abuse Treatment 2009; 37(3): 277-35. Lee, J. et. al. Comparative effectiveness of extended-release naltrexone compared to buprenorphine-naloxone for opioid relapse prevention (XEVDI) a mutitative, post nabely, anadomized trial, Lancet 2018; 391: 303-18. Tamum, et. al. Effectiveness of injectable extended-release naltrexone vs daily buprenorphine-naloxone for opioid dependence JAMA Psychiatry, 2017; 74(12):197-2105. Lundy, C et al. Extended-release naltrexone in St Louis paroless & probationers. Research Society on Alcoholism 2014. Lee, J et al. Extended-release naltrexone to prevent opioid relapse in criminal justice offenders. N Engl J Med. 2016; 74(13):1232-42. doi: 10.1056/NEMont506-409.

### REFERENCES

- + Bahji A, et al. Reduction in mortality risk with opioid agonist therapy: a systematic review and meta-analysis. Acta Psychiatrica Scandinavica. 2019;140(4):313-39.
- + Fiscella K, et al. Drug and alcohol deaths in US jails. Journal of Correctional Healthcare 2020; 26(2) 183-5.
- + Malta M, Varatharajan T, Russell C, Pang M, Bonato S, Fischer B. Opioid-related treatment, interventions, and outcomes among incarcerated persons: A systematicreview. PLoS Medicine. 2019;16(12).
- + National Academies of Sciences, Engineering, and Medicine. 2019. Medications for Opioid Use Disorder Save Lives. Washington, DC: The National Academies
- Pearce LA, Min JE, Piske M, Zhou H, Homayra F, Slaunwhite A, Irvine M, McGowan G, Nosyk B. Opioid agonist treatment and risk of mortality during opioid overdose public health emergency: population based retrospective cohort study. BMJ. 2020;388.
- Rich J, et al. Methadone continuation versus force withdrawal on incarceration in a combined US prison and jail: a randomized open label trial. Lancet. 2015; 386: 350-359.
- Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, Azocar F, Sanghavi DM. Comparative
  effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open. 2020:3(2):e19206522-.

HEALTH MANAGEMENT ASSOCIATES

Copyright © 2021 Health Management Associates, Inc. All rights reserved. PROPRIETARY and CONFIDENTIA.

### I CASE STUDY from Fairfax County Jail (FFX) - 41 yo make transferred from another jail 10 days before seen for initial M&P - 8911 den't feel like myself, high level of cavelage, trashle sleeping- some days to much vs other days not enough - Standard supplements 1156, missing and seem bounders - Standard supplements 1156, missing and seem bounders - Stoder upper release from prison 2015; relapand, became hormeless - Stoder upper release from prison 2015; relapand, became hormeless - Stoder upper release from prison 2015; relapand, became hormeless - Stoder upper release from prison 2015; relapand, became hormeless - Hormeless from prison 2015; relapand, became hormeless and prison 2015; relapand, became hormeless - Hormeless from prison 2015; relapand became from 2015; relapand became from

HEALTH MANAGEMENT ASSOCIATES

### | CONTINUING EDUCATION

- + If you are interested in receiving educational credit for this session, please indicate this on the evaluation form.
- + You will receive a follow up email with an evaluation to complete.
- + You will need to complete the evaluation in order to receive credit.

HEALTH MANAGEMENT ASSOCIATES

right © 2021 Health Management Associates, Inc. All rights reserved. PROPRIETARY and CONFIDENTIA